Specific Binding of the Pathogenic Prion Isoform: Development and Characterization of a Humanized Single-Chain Variable Antibody Fragment
2011

Humanized Antibody Fragment for Prion Diseases

publication Evidence: moderate

Author Information

Author(s): Nives Škrlj, Tanja Vranac, Mara Popović, Vladka Čurin Šerbec, Marko Dolinar

Primary Institution: University of Ljubljana, Slovenia

Hypothesis

Can a humanized single-chain variable antibody fragment maintain the binding affinity and specificity of the original murine antibody while reducing immunogenicity?

Conclusion

The humanized scFv V5B2 retains the binding properties of the original murine antibody and may serve as a potential therapeutic reagent for prion diseases.

Supporting Evidence

  • The humanized scFv V5B2 was designed to minimize immunogenicity while retaining binding specificity.
  • Both murine and humanized scFvs specifically label PrPSc deposits in brain tissue.
  • The final humanized variant showed comparable binding affinity to the original murine antibody.

Takeaway

Scientists made a version of an antibody that can recognize a harmful protein in the brain without causing problems in humans. This could help treat diseases caused by that protein.

Methodology

The study involved humanizing a murine monoclonal antibody by introducing mutations to reduce immunogenicity while maintaining binding affinity, followed by expression and purification of the humanized scFv.

Limitations

The study does not provide clinical data on the immunogenicity of the humanized antibody.

Digital Object Identifier (DOI)

10.1371/journal.pone.0015783

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication